Total Payments
$5,857
2024 Payments
$1,407
Companies
26
Transactions
366
Medicare Patients
1,816
Medicare Billing
$109,252
Payment Breakdown by Category
Food & Beverage$5,622 (96.0%)
Education$234.98 (4.0%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $5,622 | 363 | 96.0% |
| Education | $234.98 | 3 | 4.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $1,247 | 92 | $0 (2024) |
| Novo Nordisk Inc | $987.57 | 97 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $875.95 | 18 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $562.10 | 30 | $0 (2022) |
| Lilly USA, LLC | $424.52 | 29 | $0 (2024) |
| Astellas Pharma US Inc | $381.69 | 12 | $0 (2024) |
| Amgen Inc. | $326.00 | 29 | $0 (2023) |
| Amarin Pharma Inc. | $266.22 | 14 | $0 (2022) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $159.00 | 10 | $0 (2024) |
| Merck Sharp & Dohme LLC | $85.46 | 5 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,407 | 72 | ABBVIE INC. ($451.39) |
| 2023 | $1,145 | 71 | ABBVIE INC. ($330.46) |
| 2022 | $1,205 | 98 | Novo Nordisk Inc ($276.25) |
| 2021 | $2,100 | 125 | Janssen Pharmaceuticals, Inc ($428.98) |
All Payment Transactions
366 individual payment records from CMS Open Payments — Page 1 of 15
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/16/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $8.43 | General |
| Category: Diabetes | ||||||
| 11/07/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $11.43 | General |
| Category: NEUROSCIENCE | ||||||
| 11/06/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $13.84 | General |
| Category: DIABETES | ||||||
| 11/01/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $8.17 | General |
| Category: Diabetes | ||||||
| 10/18/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $8.01 | General |
| Category: Diabetes | ||||||
| 10/16/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $15.03 | General |
| Category: Diabetes | ||||||
| 10/09/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $13.53 | General |
| Category: NEUROSCIENCE | ||||||
| 10/03/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $5.62 | General |
| Category: Diabetes | ||||||
| 09/21/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $9.79 | General |
| Category: Diabetes | ||||||
| 09/16/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $20.70 | General |
| Category: NEUROSCIENCE | ||||||
| 09/12/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $11.25 | General |
| Category: NEUROSCIENCE | ||||||
| 09/11/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $19.82 | General |
| Category: PSYCHIATRY | ||||||
| 09/09/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $16.70 | General |
| Category: NEUROSCIENCE | ||||||
| 09/06/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $8.67 | General |
| Category: Diabetes | ||||||
| 08/31/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $8.37 | General |
| 08/28/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $15.74 | General |
| Category: NEUROSCIENCE | ||||||
| 08/28/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $2.63 | General |
| Category: NEUROSCIENCE | ||||||
| 08/19/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $15.00 | General |
| Category: NEUROSCIENCE | ||||||
| 08/14/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $16.18 | General |
| Category: DIABETES | ||||||
| 08/07/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $22.75 | General |
| 07/30/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $48.24 | General |
| Category: Respiratory | ||||||
| 07/27/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $12.43 | General |
| 07/23/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $12.50 | General |
| Category: NEUROSCIENCE | ||||||
| 07/15/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $18.62 | General |
| Category: NEUROSCIENCE | ||||||
| 07/15/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $16.85 | General |
| Category: Diabetes | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 294 | 522 | $54,446 | $19,944 |
| 2022 | 4 | 264 | 347 | $33,561 | $13,184 |
| 2021 | 10 | 726 | 1,173 | $107,157 | $49,253 |
| 2020 | 6 | 532 | 782 | $61,682 | $26,871 |
Total Patients
1,816
Total Services
2,824
Medicare Billing
$109,252
Procedure Codes
26
All Medicare Procedures & Services
26 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 65 | 121 | $26,741 | $9,031 | 33.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 91 | 163 | $24,450 | $8,539 | 34.9% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 99 | 198 | $1,980 | $1,663 | 84.0% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 13 | 13 | $598.00 | $381.68 | 63.8% |
| 90686 | Influenza vaccine, quadrivalent, preservative free, 0.5 ml dosage | Office | 2023 | 14 | 14 | $378.00 | $284.70 | 75.3% |
| 81002 | Urinalysis, manual test | Office | 2023 | 12 | 13 | $299.00 | $44.33 | 14.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 123 | 172 | $26,144 | $9,095 | 34.8% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 26 | 26 | $4,394 | $2,778 | 63.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 19 | 20 | $2,120 | $926.59 | 43.7% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 96 | 129 | $903.00 | $383.94 | 42.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 207 | 328 | $49,856 | $22,585 | 45.3% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2021 | 96 | 96 | $16,224 | $10,499 | 64.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 85 | 100 | $21,200 | $9,367 | 44.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 89 | 113 | $12,024 | $4,588 | 38.2% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2021 | 180 | 392 | $2,744 | $1,176 | 42.9% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 12 | 49 | $1,764 | $353.78 | 20.1% |
| 86318 | Test for detection of infectious agent antibody, qualitative or semiquantitative | Office | 2021 | 14 | 14 | $910.00 | $253.26 | 27.8% |
| 87804 | Detection test by immunoassay for influenza virus | Office | 2021 | 14 | 14 | $350.00 | $231.70 | 66.2% |
| 93000 | Routine ekg using at least 12 leads including interpretation and report | Office | 2021 | 17 | 18 | $1,350 | $136.50 | 10.1% |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | Office | 2021 | 12 | 49 | $735.00 | $63.34 | 8.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 189 | 249 | $37,809 | $16,379 | 43.3% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 133 | 189 | $20,034 | $9,131 | 45.6% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2020 | 175 | 267 | $1,869 | $801.00 | 42.9% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2020 | 12 | 33 | $1,180 | $299.84 | 25.4% |
| 87804 | Detection test for influenza virus | Office | 2020 | 12 | 13 | $325.00 | $215.15 | 66.2% |
About Anna Schubert
Anna Schubert is a Family healthcare provider based in Dayton, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/22/2019. The National Provider Identifier (NPI) number assigned to this provider is 1619538592.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Anna Schubert has received a total of $5,857 in payments from pharmaceutical and medical device companies, with $1,407 received in 2024. These payments were reported across 366 transactions from 26 companies. The most common payment nature is "Food and Beverage" ($5,622).
As a Medicare-enrolled provider, Schubert has provided services to 1,816 Medicare beneficiaries, totaling 2,824 services with total Medicare billing of $109,252. Data is available for 4 years (2020–2023), covering 26 distinct procedure/service records.
Ad
Practice Information
- Specialty Family
- Location Dayton, OH
- Active Since 06/22/2019
- Last Updated 10/19/2019
- Taxonomy Code 363LF0000X
- Entity Type Individual
- NPI Number 1619538592
Products in Payments
- QULIPTA (Drug) $581.09
- XARELTO (Drug) $562.10
- Ozempic (Drug) $432.18
- BREZTRI (Drug) $370.45
- UBRELVY (Drug) $339.25
- VRAYLAR (Drug) $326.58
- LOKELMA (Drug) $271.56
- Vascepa (Drug) $266.22
- Rybelsus (Drug) $253.56
- TRULICITY (Drug) $202.87
- Otezla (Drug) $199.73
- JARDIANCE (Drug) $187.72
- FARXIGA (Drug) $172.06
- MOUNJARO (Drug) $162.74
- Aimovig (Biological) $126.27
- MYRBETRIQ (Drug) $86.28
- FREESTYLE LIBRE 3 (Device) $69.93
- REXULTI (Drug) $66.80
- Wegovy (Drug) $61.89
- AIRSUPRA (Drug) $61.88
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Doctors in Dayton
Leigh Pansch, Np, NP
Family — Payments: $454,205
Family $454,205
Nafresha Abuaun, Pmhnp-Bc, Fnp-Bc, PMHNP-BC, FNP-BC
Family — Payments: $10,047
Family $10,047
Mrs. Elissa Reed, Fnp-C, FNP-C
Family — Payments: $9,791
Family $9,791
Mrs. Caitlyn Frantz, Np-C, NP-C
Family — Payments: $8,564
Family $8,564
Dilfuza Makhmudova
Family — Payments: $6,762
Family $6,762
Jacqueline Papalios, Fnp-C, FNP-C
Family — Payments: $6,254
Family $6,254